1 suspended, 1 terminated, 1 withdrawn. 3 Phase 1, 3 Phase 2.
By phase and status
Follow H1299 Cell Lysates: new trials by email Literature Review of H1299 Cell Lysates trials Research Report on H1299 Cell Lysates
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
Montanide (Registered Trademark) ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803 - Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 30 | 2026-10-27 | 2026-10-22 |
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer
Nivolumab, Entinostat, Montanide(R) ISA-51 VG Adjuvant - Neoplasms, Esophageal Neoplasms | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | | 2024-08-02 | 2024-08-05 |
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
H1299 cell lysates, Cyclophosphamide, Celecoxib - Thoracic Sarcomas, Thorasic Cancers | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 21 | 2014-09-03 | 2022-01-26 |
Conditions studied
Neoplasm, Residual (2) · Carcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Esophageal Neoplasms (1) · Melanoma (1) · Neoplasms (1) · Sarcoma (1)
Sponsors
National Cancer Institute (NCI) (3)
Countries
United States (3)
Top investigators
David S Schrump, M.D. (3)
Results publications
PMID 34430349